Navigation Links
Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders Approve All Resolutions
Date:11/4/2013

ZURICH, November 4, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Extraordinary Shareholders' Meeting the announced capital increase in particular.

The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 28 shareholders. 12,673,384 shares or 56.55% of a total of 22,411,431 shares were represented.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma. CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far. Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

Forward Looking Statements  This media release contains certain forward-looking statements that involve risks and uncertainties th
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. How Companies Can Provide Extraordinary New B2B Products with Extraordinary Product Launches - A Sales Momentum White Paper
2. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
3. Leading Technology Incubator Honors Extraordinary Entrepreneurs
4. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Hadasit Bio-Holdings CEO Letter to Shareholders
7. Medifirst Solutions, Inc. Announces Further Update To Shareholders
8. Letter from Alliqua CEO, Dave Johnston, to Shareholders
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... 2011  AMPAC Fine Chemicals LLC (AFC), ... announced it has concluded an agreement with Chimerix, Inc. ... the API in Chimerix,s broad spectrum antiviral drug candidate, ... treatment of smallpox.  Chimerix will provide the investigational drug ...
... Neurologix, Inc. (OTCBB: NRGX), a biotechnology company ... of the brain and central nervous system, today announced its ... 30, 2011. For the three months ended June ... million, as compared with a net loss of approximately $4.5 ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that ... Life Sciences Management Access Conference at the Le Parker Meridien ... presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. ...   Interleukin,s management team will be available for ...
Cached Biology Technology:AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 2AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 3AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 4Neurologix Announces Second Quarter 2011 Financial Results 2Neurologix Announces Second Quarter 2011 Financial Results 3Neurologix Announces Second Quarter 2011 Financial Results 4Neurologix Announces Second Quarter 2011 Financial Results 5Neurologix Announces Second Quarter 2011 Financial Results 6Neurologix Announces Second Quarter 2011 Financial Results 7Neurologix Announces Second Quarter 2011 Financial Results 8Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... the bugs. The rates of drug-resistant bacteria infecting patients ... increasing steadily in recent years, according to two new ... Diseases, now available online. , Drug resistance in microorganisms ... prescribing and overuse of antibiotics. These drug-resistant "superbugs" can ...
... a healthy dose of fat, suggests a new study published ... directly from the diet or generated from sugars spark a ... blood levels of sugar, cholesterol, and other fats, according to ... those critical metabolic pathways in motion, they found. The findings ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Two studies document rise of superbugs in the environment 2Two studies document rise of superbugs in the environment 3Fat's fate depends on its source 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: